You're a veteran medical doctor mbbs md dm gastroenterologist and hematologist from aiims delhi. Kindly review these reports and comment. No symptoms, no loss of appetite, moderate alcohol history but hardly 10 ml once a week.
Reading File
analyse_media
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Running Command
Reading File
Searching PubMed
"CAP score" AND "hepatic steatosis" AND management
Running Command
Excellent - I now have a comprehensive picture of all the reports. Let me compile a thorough clinical review.
Clinical Review - Vinod Chhiber, 75M | AIIMS Delhi Gastroenterology & Hematology
Reports reviewed:
- FibroScan (FibroScan by Achosens, Diabetes Liver Clinic - Zydus), dated 2/7/26
- Comprehensive Blood Panel (Healthians), dated 2 April 2026
FIBROSCAN FINDINGS
| Parameter | Value | Interpretation |
|---|---|---|
| CAP Score | 334 dB/m | Grade III Steatosis (>67% fat) |
| LSM (Liver Stiffness) | 6.9 kPa | F0-F1 borderline (No/Minimal Fibrosis) |
CAP Score 334 dB/m - Grade III Hepatic Steatosis
This is a significant finding. A CAP >292 dB/m places him firmly in Grade III steatosis, meaning more than 67% of hepatocytes are estimated to be fatty. This is severe fatty liver disease. Given the very minimal alcohol intake you describe (10 ml once a week - well below any hepatotoxic threshold), this is almost certainly Metabolic-Associated Steatotic Liver Disease (MASLD), the updated nomenclature (previously NAFLD). The attending physician has already prescribed Tab. Lipaglyn 4 mg (Saroglitazar), a PPAR-α/γ dual agonist approved in India specifically for MASLD/NASH - this is an appropriate first-line liver-directed choice.
LSM 6.9 kPa - Reassuringly Low
This is excellent news and must be emphasised to the patient. An LSM <7 kPa effectively rules out advanced hepatic fibrosis (F3-F4). As per Harrison's (2025): "A VCTE-derived liver stiffness measurement <8 kPa can be used to rule out advanced fibrosis." There is no cirrhosis, no portal hypertension at this stage. The liver architecture appears preserved. Despite severe steatosis, fibrosis has not set in - this is the window for effective intervention.
One caveat: LSM can be mildly elevated by obesity, non-fasting state, or hepatic congestion. At 6.9 kPa it is very close to the F0/F1 boundary (7 kPa), so this should be re-evaluated in 6-12 months, particularly after lifestyle modification and Saroglitazar therapy.
BLOOD REPORT REVIEW (2 April 2026)
BMI - IMPORTANT FINDING
The advisory page lists: Height 5'6", Weight 94 kg, BMI 32.53. This is Grade I Obesity and almost certainly the primary driver of the severe hepatic steatosis. This is the single most important modifiable risk factor.
(Note: the FibroScan card left height/weight/BMI blank - the physician should have recorded this for accurate CAP interpretation.)
Liver Function Tests - All Normal
| Test | Value | Reference |
|---|---|---|
| Total Bilirubin | 0.60 mg/dL | Normal |
| AST/SGOT | 23 U/L | Normal |
| ALT/SGPT | 26.3 U/L | Normal |
| ALP | 38.5 U/L | Low-normal (new ref: 43-115) |
| GGT | 15.8 U/L | Normal |
| Albumin | 4.04 g/dL | Normal |
| Total Protein | 7.06 g/dL | Normal |
| A:G Ratio | 1.34 | Normal |
| AST:ALT Ratio | 0.87 | Normal (<1, consistent with non-alcoholic pattern) |
This is a very important finding: liver enzymes are completely normal. This is not unusual in MASLD - many patients with significant steatosis have normal transaminases. The normal AST:ALT ratio <1 is also reassuring and consistent with the metabolic/non-alcoholic etiology (alcoholic hepatitis typically gives ratio >2). ALP at 38.5 is flagged as marginally below the new reference range (43-115 changed Feb 2026) - this is clinically insignificant.
Glycemic Status - Prediabetes, Needs Attention
| Test | Value | Interpretation |
|---|---|---|
| Fasting Glucose | 86.76 mg/dL | Normal |
| HbA1c | 5.9% | Prediabetes (ADA: 5.7-6.4%) |
HbA1c 5.9% places him squarely in the prediabetes range. This is highly relevant because insulin resistance is a key pathogenic driver of MASLD. Saroglitazar (Lipaglyn) addresses this dual metabolic burden through its PPAR-α/γ mechanism - improving both liver fat and insulin sensitivity. No formal diabetes diagnosis at this point, but this needs monitoring every 6 months with repeat HbA1c and fasting glucose. Lifestyle modification is the primary intervention here.
Lipid Profile - Largely Reassuring
| Test | Value | Interpretation |
|---|---|---|
| Total Cholesterol | 162.5 mg/dL | Optimal |
| Triglycerides | 115.7 mg/dL | Normal (<150) |
| HDL | 43.2 mg/dL | Low-borderline (men: ideally >40, preferably >60) |
| LDL | 96.18 mg/dL | Near-optimal |
| Non-HDL | 119.3 mg/dL | Acceptable |
Lipid profile is broadly satisfactory. HDL is slightly low at 43.2 mg/dL in a 75-year-old male - can be improved with aerobic exercise and reduction of refined carbohydrates. Triglycerides are normal, which is a positive marker. No statin indication based purely on lipids at this stage, but overall cardiovascular risk should be formally assessed given age, obesity, and prediabetes.
Hematology - Two Points Require Follow-up
| Test | Value | Reference | Status |
|---|---|---|---|
| Haemoglobin | 13.3 g/dL | 13.0-17.0 | Low-normal |
| PCV/Hematocrit | 39.5% | 40.0-50.0% | Marginally low |
| RBC | 4.42 × 10⁶/µL | 4.50-5.50 | Marginally low |
| Platelets | 125.3 × 10³/µL | 150-410 | Low |
| Eosinophils | 7.1% | 1-6% | Mildly elevated |
| MPV | 12.4 fL | 7-9 fL | Elevated |
| RDW-CV | 14.1% | 11.6-14.0% | Borderline high |
Thrombocytopenia (Platelets 125.3 × 10³/µL): This is a clinically important finding. Mild thrombocytopenia in a patient with known hepatic steatosis raises a few considerations:
- In the context of liver disease - Platelet count is one of the parameters used in FIB-4 scoring to assess advanced fibrosis risk. Harrison's specifically notes that "thrombocytopenia" is a feature suggesting advanced fibrosis that might prompt liver biopsy evaluation. However, with an LSM of only 6.9 kPa, advanced fibrosis/cirrhosis is very unlikely to be the cause here.
- More likely causes - At 75 years, age-related bone marrow changes, early myelodysplastic changes, or viral suppression (previous or subclinical) are more likely. The elevated MPV (12.4 fL) with a low platelet count is consistent with a pattern of enhanced platelet turnover or peripheral destruction.
- Previous count was 153 × 10³ in 2018 - This represents a drop of ~28 × 10³ over 8 years, which is a slow progressive decline and warrants monitoring.
Recommendation: Peripheral blood smear examination (as already suggested by the lab advisory) is warranted. FIB-4 index calculation would also be useful:
FIB-4 = (Age × AST) / (Platelets × √ALT) = (75 × 23) / (125.3 × √26.3) = 1725 / (125.3 × 5.13) = 1725 / 642.9 = 2.68
A FIB-4 of 2.68 falls at the borderline of the intermediate/high-risk zone (≥2.67 per Harrison's 2025 guidelines for MASLD). This is the threshold at which secondary non-invasive testing with ELF panel or imaging-based methods is recommended. This is somewhat in mild discordance with the LSM of 6.9 kPa (reassuringly low). This discordance is partly driven by the low platelet count.
Eosinophilia (7.1%, AEC 0.42): Mild, likely non-significant. Could represent allergic/atopic background, or rarely parasitic infection. Not clinically alarming but worth noting. Stool examination can be considered.
Kidney Function - Normal, With Minor Electrolyte Points
| Test | Value | Status |
|---|---|---|
| Creatinine | 0.85 mg/dL | Normal |
| eGFR | 90.62 mL/min/1.73m² | Normal (G2 borderline normal) |
| Uric Acid | 7.9 mg/dL | High (ref 3.5-7.2) |
| Sodium | 134 mmol/L | Marginally low (136-146) |
| Chloride | 100 mmol/L | Marginally low (101-109) |
Hyperuricemia (7.9 mg/dL): Mild asymptomatic hyperuricemia. At 75 years with no symptoms mentioned, treatment is not mandatory, but dietary advice is appropriate - reduce red meat, shellfish, organ meats, and fructose-rich beverages. Monitor for gout. Uric acid also has an independent association with metabolic syndrome and MASLD.
Mild hyponatremia/hypochloridemia - Sodium 134, Chloride 100 - these are very mild borderline values and could reflect dietary pattern, mild dilutional effect, or lab variation. Electrolytes should be rechecked in 4-6 weeks. Clinically, the patient is asymptomatic.
Inflammatory Markers
| Test | Value | Reference | Status |
|---|---|---|---|
| CRP | 1.33 mg/L | <5 | Normal |
| hs-CRP | 1.12 mg/L | <1.0 | Mildly elevated |
hs-CRP 1.12 mg/L falls in the intermediate cardiovascular risk category (1-3 mg/L per ACC/AHA guidelines). This is consistent with the metabolic syndrome milieu (obesity + prediabetes + MASLD). Not alarming, but is a cardiovascular risk marker. At age 75, this should factor into the global cardiovascular risk assessment.
Other Parameters - All Normal
- TSH 1.73 µIU/mL - Normal (rules out hypothyroidism as contributor to dyslipidemia/obesity)
- T3 0.86 ng/mL - Very marginally at lower limit; T4 normal; TSH normal - subclinically of no concern
- Vitamin D 36.71 ng/mL - Sufficient (>30 ng/mL)
- Vitamin B12 323 pg/mL - Normal
- Iron studies - Normal transferrin saturation (21.3%), no iron overload or deficiency
- PSA 1.00 ng/mL - Normal for age 75, no prostate concern
- Urine microalbumin <7 mg/L - Normal, good kidney filtration barrier
- RA Factor <10 - Negative
- Amylase 59 U/L - Normal
PHYSICIAN'S PRESCRIPTION (FibroScan card)
The prescribing physician has written:
- Tab. Rabeprazole 20 mg - PPI, presumably for gastric protection/reflux. Appropriate.
- Tab. Lipaglyn 4 mg (Saroglitazar) - PPAR-α/γ agonist. This is the correct and evidence-based choice for MASLD in India. It is approved by DCGI for diabetic dyslipidemia and NASH. Starting at 4 mg is appropriate.
OVERALL CLINICAL IMPRESSION
This 75-year-old asymptomatic male with obesity (BMI 32.5) and prediabetes (HbA1c 5.9%) has:
- Severe hepatic steatosis (Grade III, CAP 334) - almost certainly MASLD, driven by obesity and insulin resistance. Normal liver enzymes.
- No significant hepatic fibrosis (LSM 6.9 kPa) - this is the most reassuring finding. The liver has not progressed to fibrosis/cirrhosis. This is a good prognostic sign.
- Borderline FIB-4 (2.68) - warrants a secondary non-invasive fibrosis assessment (ELF panel or repeat VCTE in 6-12 months) given mild discordance with platelet count.
- Mild thrombocytopenia (platelets 125.3) with rising MPV - needs peripheral smear and clinical monitoring; likely not hepatogenic given low LSM.
- Asymptomatic hyperuricemia - dietary management.
- Borderline electrolytes - recheck in 4-6 weeks.
- Mildly elevated hs-CRP - intermediate CV risk marker.
MY RECOMMENDATIONS
Immediate:
- Continue Saroglitazar 4 mg - appropriate liver-directed therapy
- Peripheral blood smear examination to evaluate mild thrombocytopenia
- Recheck electrolytes (Na, Cl) in 4-6 weeks
- Calculate and document FIB-4 formally; consider ELF panel or repeat FibroScan in 6-12 months
Lifestyle (non-negotiable for MASLD Grade III):
- Weight loss of even 5-10% (4.7-9.4 kg) can significantly reduce hepatic fat content and may improve HbA1c
- Mediterranean dietary pattern - reduce refined carbohydrates, fructose, and saturated fats; increase olive oil, nuts, vegetables, fish
- Moderate aerobic exercise: 150 minutes/week (brisk walking is suitable at this age)
- Avoid even the occasional alcohol completely, given Grade III steatosis - 10 ml/week is minimal but adds no benefit and zero alcohol is the right target now
Monitoring Plan:
- HbA1c every 6 months (prediabetes surveillance)
- LFTs + CBC every 3 months initially on Saroglitazar
- Repeat FibroScan (CAP + LSM) at 12 months to assess treatment response
- Uric acid and electrolytes at 3 months
- Consider abdominal ultrasound to look for spleen size, given mild thrombocytopenia
- Lipid profile at 6 months
Investigations to Consider:
- HBsAg, Anti-HCV if not done previously (to rule out co-existing viral hepatitis in a patient with MASLD - changes management)
- Peripheral smear examination (already advised by lab)
- If platelet count continues to fall, haematology referral
Bottom line: The good news is that despite severe steatosis (Grade III), there is no fibrosis yet - this is an ideal stage for intervention. With appropriate weight loss, lifestyle change, and Saroglitazar, Grade III steatosis is entirely reversible. The mild thrombocytopenia and borderline FIB-4 deserve closer follow-up but are not immediately alarming given the reassuring LSM of 6.9 kPa. Please ensure HBsAg and HCV status are checked if not already done.
This review is for clinical guidance only and should be correlated with a full clinical examination, history, and the treating physician's judgment. Not a substitute for an in-person consultation.
This is a shared conversation. Sign in to Orris to start your own chat.